Patel Priya, Robinson Paula D, Orsey Andrea, Freedman Jason L, Langevin Anne-Marie, Woods Debbie, Sung Lillian, Dupuis L Lee
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Pediatric Oncology Group of Ontario, Toronto, Ontario, Canada.
Pediatr Blood Cancer. 2016 May;63(5):887-92. doi: 10.1002/pbc.25915. Epub 2016 Jan 27.
The Children's Oncology Group (COG) has endorsed a clinical practice guideline (CPG) for acute chemotherapy-induced nausea and vomiting (CINV) prophylaxis in children with cancer. This project aims to describe current acute CINV prophylaxis practice at COG sites and the gap between this practice and CPG recommendations.
Two surveys were developed. The first survey, sent to 94 cancer control and supportive care responsible individuals (CCL RIs) at 94 COG institutions, asked if the institution had a standardized approach to practice and focused on antiemetic agent choice. The second survey, sent to 54 pharmacists at COG sites where the CCL RI indicated that there was a standardized approach to CINV prophylaxis practice, focused on antiemetic dosing. Survey results were described and analyzed for consistency with the CPG recommendations.
Among the 69 respondents to the first survey, 54 (78%) stated that their institutions have a standardized approach to CINV prophylaxis practice. However, antiemetic choice varied widely among respondents. Results from the 36 respondents to the second survey also demonstrated significant antiemetic dosing practice variability. Frequent sources of deviation from CPG recommendations were as follows: antiemetic choice when corticosteroids are contraindicated, dexamethasone dosing, aprepitant use in children less than 12 years, and aprepitant use in the presence of a known or suspected drug interaction.
There is a great diversity in the CINV prophylaxis provided to children with cancer at COG sites. Concerted strategies are required to improve awareness of the current CINV prophylaxis CPG and to facilitate CPG-consistent CINV prophylaxis.
儿童肿瘤学组(COG)认可了一项针对癌症患儿急性化疗引起的恶心和呕吐(CINV)预防的临床实践指南(CPG)。本项目旨在描述COG各机构目前急性CINV预防的实践情况以及该实践与CPG建议之间的差距。
开展了两项调查。第一项调查发送给94个COG机构的94名癌症控制和支持治疗负责人(CCL RI),询问该机构是否有标准化的实践方法,并侧重于止吐药的选择。第二项调查发送给CCL RI表示有CINV预防实践标准化方法的COG机构的54名药剂师,侧重于止吐药的剂量。描述并分析调查结果,以确定其与CPG建议的一致性。
在第一项调查的69名受访者中,54名(78%)表示其机构有CINV预防实践的标准化方法。然而,受访者之间止吐药的选择差异很大。第二项调查的36名受访者的结果也显示止吐药剂量实践存在显著差异。与CPG建议的常见偏差来源如下:禁忌使用糖皮质激素时的止吐药选择、地塞米松剂量、12岁以下儿童使用阿瑞匹坦以及在已知或疑似药物相互作用的情况下使用阿瑞匹坦。
COG各机构为癌症患儿提供的CINV预防措施存在很大差异。需要采取协调一致的策略来提高对当前CINV预防CPG的认识,并促进与CPG一致的CINV预防。